Pharmaceutical California, USA-based Titan Pharma and its partner, Braeburn Pharmaceuticals, have agreed in principle with the US Food and Drug Administration on the design of a clinical study in support of the New Drug Application for Probuphine (buprenorphine), the company’s investigational subdermal implant for the maintenance treatment of opioid dependence. 4 March 2014